Association of ERBB mutations with clinical outcomes of afatinib-or erlotinib-treated patients with lung squamous cell carcinoma: secondary analysis of the LUX-Lung …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos… - JAMA …, 2018 - jamanetwork.com
Importance Treatment choice for lung squamous cell carcinoma could be aided by
identifying predictive biomarkers. Objective To assess whether patient outcomes in the LUX …
被引用次数：58 相关文章
[PDF] ksyrigos.gr

[PDF][PDF] Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos, KH Lee… - 2018 - ksyrigos.gr
OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated
with ERBB gene family member aberrations in tumor specimens. DESIGN, SETTING, AND …

Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX …

G Goss, E Felip, M Cobo, S Lu, K Syrigos, K Lee… - JAMA …, 2018 - cris.unibo.it
Importance Treatment choice for lung squamous cell carcinoma could be aided by
identifying predictive biomarkers. Objective To assess whether patient outcomes in the LUX …

Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos… - JAMA …, 2018 - europepmc.org
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients
With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized …
[PDF] academia.edu

[PDF][PDF] Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos, KH Lee… - JAMA, 2018 - academia.edu
OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated
with ERBB gene family member aberrations in tumor specimens. DESIGN, SETTING, AND …
[HTML] nih.gov

[HTML][HTML] Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos… - JAMA …, 2018 - ncbi.nlm.nih.gov
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated
Patients With Lung Squamous Cell Carcinoma - PMC Back to Top Skip to main content NIH …

[引用][C] Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma

GD Goss, E Felip, M Cobo, S Lu, K Syrigos, KH Lee… - JAMA Oncology, 2018 - cir.nii.ac.jp
Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated
Patients With Lung Squamous Cell Carcinoma | CiNii Research CiNii 国立情報学研究所 学術 …

Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos… - JAMA …, 2018 - pubmed.ncbi.nlm.nih.gov
Importance Treatment choice for lung squamous cell carcinoma could be aided by
identifying predictive biomarkers. Objective To assess whether patient outcomes in the LUX …

Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos… - JAMA …, 2018 - europepmc.org
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients
With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized …
[PDF] academia.edu

[PDF][PDF] Association of ERBB Mutations With Clinical Outcomes of Afatinib-or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the …

GD Goss, E Felip, M Cobo, S Lu, K Syrigos, KH Lee… - JAMA, 2018 - academia.edu
OBJECTIVE To assess whether patient outcomes in the LUX-Lung 8 trial were associated
with ERBB gene family member aberrations in tumor specimens. DESIGN, SETTING, AND …